RecruitingNot ApplicableNCT07445438

Feasibility of a Multi-omics Platform for Hematological Malignancies

Sponsor

Azienda Ospedaliero-Universitaria di Parma

Enrollment

1,040 participants

Start Date

Mar 31, 2025

Study Type

INTERVENTIONAL

Conditions

Acute Leukemia Chronic Leukemia Lymphoproliferative Disorders Myeloproliferative Disorders Myelodysplastic Disorders Myeloma, Multiple

Summary

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new advanced laboratory platform that analyzes multiple types of biological data at the same time — genes, proteins, and other molecular information — to help doctors diagnose and understand blood cancers (such as leukemia, lymphoma, or myeloma) more precisely. The goal is to see if this combined approach gives better diagnostic results than current methods. **You may be eligible if:** - You are older than 2 years of age - You have been previously diagnosed with a blood cancer (for the retrospective part of the study) - You are currently being evaluated for a suspected blood cancer or relapse, and need a bone marrow or blood sample as part of your diagnosis (for the prospective part) **You may NOT be eligible if:** - You are 2 years old or younger - You do not have a diagnosis or clinical suspicion of a blood cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMulti-omics analyses

The focus of our scientific approach is based on multi-omics analyses: NGS (Next Generation Sequencing analysis), Bulk Transcriptomics, Single-cell resolution, Single-cell transcriptomics and phosphoproteomics.

BIOLOGICALFunctional tests

Functional analyses will be performed on primary sample from each enrolled patient. Malignant cells are cultered and incubated with a specific library of drugs (300 drugs) at four different concentrations for 72 hours.